Dublin, April 06, 2023 (GLOBE NEWSWIRE) -- The "Lenvatinib + pembrolizumab Emerging Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering.

Lenvatinib represents a promising treatment option for patients with anaplastic thyroid cancer and appears to improve patients' average overall survival by almost 4 months. A single-institution ...

Researchers have characterized common adverse reactions to combination lenvatinib and pembrolizumab in patients with advanced renal cell carcinoma. Researchers have characterized common adverse ...

Among a cohort of insured patients with cancer, the median total monthly cost of oral lenvatinib was $17,253, and 75% of patients paid $100 or less out of pocket per month for the drug. Objective ...

Following on from information provided to NICE by the company in October 2022, the appraisal of Lenvatinib with pembrolizumab for untreated advanced or unresectable hepatocellular carcinoma [ID3930] ...